In 1994 the Institute of Medicine's Vaccine Safety Committee concluded that “the evidence establishes a causal relation between measles-mumps-rubella vaccine (MMR) and thrombocytopenia. On the basis of data from Finland and Sweden, the incidence seems to be on the order of 1 per 30 000 to 40 000 vaccinated children.” Although data available at that time were not optimal, the Committee's conclusions have stood the test of time and are supported by the accretion of evidence in subsequent studies, including the study by France et al published in this issue of Pediatrics that found an attributable risk of 1 case of immune thrombocytopenic purpura (ITP) per 40 000 doses of MMR administered in the second year of life. Given that the annual US birth cohort is >4 million and that the first dose of MMR is routinely recommended by the Centers for Disease Control and Prevention (CDC)...

You do not currently have access to this content.